Handbook of Gastrointestinal Cancer
Format: PDF / Kindle (mobi) / ePub
Do you manage patients with gastrointestinal cancer?
Do you need a rapid reference handbook to guide you through your diagnosis and management options?
If so, then Handbook of Gastrointestinal Cancer is the book for you, providing clear, practical guidance to the diagnosis and clinical management of all forms of GI cancer, in a highly accessible format. Perfect for GI/Oncology trainees and junior gastroenterologists/oncologists and designed for point-of-care consultation, each chapter is structured in a uniform way and contains a variety of handy text features to help the reader such as case histories, key practice points, key weblinks and potential pitfalls
The authors emphasize the best clinical assessment and management methods of patients and dedicate an entire chapter to each cancer, from esophageal to lower GI, and from biliary to pancreatic cancer.
This attractive new book features:
- Comprehensive yet quick and easy display of key points
- Case studies to illustrate cardinal lessons or dilemmas
- A fully integrated GI/oncologic approach
- An outstanding and international editor and author team of great experience
- Illustrations of key clinical or investigative features
Handbook of Gastrointestinal Cancer answers all your clinical needs and is a must-have tool on the ward for all trainee and junior gastroenterologists and oncologists.
"Handbook of GI Cancer ... does an excellent job of indicating which clinical recommendations are solidly evidence-based, and highlighting those that would benefit from further research."
—Monica M. Bertagnolli, MD, Chief, Division of Surgical Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, USA
"Handbook of Gastrointestinal Cancer is a comprehensive text that should be on the bookshelf of every physician and surgeon who deals with GI malignancies. The editors, who are internationally renowned, have assembled an all-star cast of contributing authors from around the world. The inclusion of key points and case studies, and the use of an evidence-based approach, make this a stand-out reference."
—Mark K. Ferguson, MD,Professor, Department of Surgery and The Cancer Research Center, The University of Chicago Medicine & Biological Sciences, Chicago, USA
large trials in the West have evaluated the role of extent of surgery by randomizing gastric cancer patients to either a D1 or D2 lymph node dissection. The Medical Research Council (MRC) trial of 400 patients with resectable gastric adenocarcinoma demonstrated equivalent 5-year survival rates in both groups, with increase in postoperative morbidity and mortality reported in the D2 resection arm.19 Pancreatico-splenectomy combined with D2 dissection was demonstrated as an adverse factor affecting
years of age, as HDGC is rare below this age. Individuals with CDH1 mutation at risk of HDGC are advised to undergo prophylactic gastrectomy once their growth and development has stopped, approximately at age 20. Decision regarding prophylactic surgery and exact timing should be discussed with patient in detail after discussion at multidisciplinary meeting. It is important that these patients consult with a genetic counselor and dietician before making their final decision.18 Following
al. (1996) Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg, 83(9), 1174–1185. about 42% in 1960s to about 20% currently according to Centers for Disease Control and Prevention (CDC) reports. However, this decline of cigarette smoking has been stalled and caused significant public health concerns as the U.S. failed to drop below 12%, a goal set by Healthy People 2010. In addition, there appears to be an increase in younger smokers that may lead to a recurrence in the rate of
in assessing extent of disease progression and thus determining treatment.63 Figure 5.7 describes the imaging studies available to stage CRC. X-ray The disadvantage of this technique is that all structures are projected in one plane, and although there is good contrast between air, soft tissue, and bone, the inherent soft-tissue contrast is too low to allow differentiation of various soft-tissue structures (e.g., a tumor in muscle or a metastasis in 100 Handbook of Gastrointestinal Cancer
continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist, 12, 38–50. Buyse, M., Zeleniuch-Jacquotte, A., Chalmers, T.C. (1988) Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA, 259, 3571–3578. Bedikian, A.Y., Valdivieso, M., Mavligit, G.M., et al. (1978) Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker’s Antifol and levamisole. Cancer, 42, 2169–2176. Buroker, T.R., Moertel, C.G., Fleming, T.R., et al.